What is Adaptimmune Therapeutics plc (ADAPY)?

Adaptimmune Therapeutics plc (ADAPY) is a stock in the Healthcare sector, Biotechnology industry. View full analysis on Stocks360.

What is the current price of ADAPY?

The current price of ADAPY is $0.03. Prices are updated in real time on Stocks360.

What is ADAPY's price-to-earnings (PE) ratio?

ADAPY's trailing twelve-month PE ratio is -0.09, based on current price and earnings per share data available on Stocks360.

What is ADAPY's market capitalization?

ADAPY's market capitalization is $6,891,341.00, placing it in the small-cap tier.

Adaptimmune Therapeutics plc (ADAPY)

Stock analysis · OTC · Healthcare · Biotechnology

$0.03

Market Cap

$6.89M

PE (TTM)

-0.09

EPS (TTM)

N/A

Dividend Yield

0.00%

Beta

0.75

Day Range

$0.03 – $0.03

52-wk Range

$0.00 – $0.36

Avg Volume

N/A

Volume

28.09K

Adaptimmune Therapeutics plc (ADAPY) is a publicly traded company in the Healthcare sector. Latest price: $0.03. Market cap $6.89M. Trailing PE -0.09. Sign in to Stocks360 for full DCF valuation, fundamentals, technicals, and AI-driven analysis.

Get full analysis → Short-Term Analysis →

1-Year Price

2025-10-30 · $0.05 2026-10-29 · $0.03 (-48.82%)

Earnings

Most Recent

Apr 23, 2026

EPS $-0.03 vs est. $-0.06

Beat by $0.03

Next Earnings

Nov 12, 2026

EPS estimate $-0.02

Proprietary Signals

Signal snapshot temporarily unavailable.

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc is a commercial-stage biopharmaceutical company specializing in innovative cell therapies for cancer patients, primarily operating in the United States and the United Kingdom. Its pipeline includes TECELRA (also known as famitresgene autoleucel or afami-cel), an autologous T-cell immunotherapy that employs genetically modified cells to treat adults with advanced, unresectable, or metastatic synovial sarcoma. The company is also advancing Lete-cel for synovial sarcoma and myxoid liposarcoma, and ADP-5701, currently in Phase 1 clinical trials for head and neck cancer. Additionally, Adaptimmune is developing T-cell therapies engineered to target PRAME (ADP-600) and CD70 (ADP-520). The firm engages in strategic collaborations, notably with Galapagos for a clinical proof-of-concept trial of uza-cel (ADP-5701) in head and neck cancer, leveraging Galapagos' decentralized manufacturing platform. Further partnerships include a licensing agreement with Noile-Immune Biotech, Inc. and a strategic alliance with the MD Anderson Cancer Center. Established in 2008, Adaptimmune Therapeutics plc is headquartered in Abingdon, United Kingdom.

Valuation

Trailing twelve months. Multiples relative to current market price.
P/E (TTM)	-0.09×
P/S (TTM)	1.16×
P/B	0.07×
PEG	0.00×
P/FCF (TTM)	-0.09×
EV / EBITDA	0.09×
EV / Sales	-0.84×
Earnings Yield	1153.85%
Free Cash Flow Yield	-1101.76%

Fundamentals

Trailing twelve months. Source: financial statements via market data.
Enterprise Value	-$4.98M
Net Income (TTM)	$79.52M
Free Cash Flow (TTM)	-$75.93M
Net Debt	-$11.87M
Working Capital	$23.08M
Gross Margin	100.00%
Operating Margin	-1225.05%
Net Margin	425.49%
Return on Equity	115.05%
Return on Invested Capital	-157.59%